EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes

Aleksander L Hansen iD, Mette K Andersen iD, Leonie M Engelhard iD, Charlotte Brøns iD, Torben Hansen iD, Jens S Nielsen iD, Peter Vestergaard iD, Kurt Højlund iD, Niels Jessen iD, Michael H Olsen iD, Reimar W Thomsen iD, Allan Vaag iD

Diabetes, Obesity and Metabolism · 2025-04 · 27 (4) · 2002-2011

DOI: 10.1111/dom.16193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.01.2025. Verfasst von Aleksander L Hansen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Transcription Factor 7-Like 2 Protein, Diabetic Angiopathies, Diabetes Complications. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Region Syddanmark, Sundhedsstyrelsen, Danish Agency for Science and Higher Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

TCF7L2 rs7903146 is the most impactful single genetic risk variant for type 2 diabetes. However, its role on disease progression, complications and mortality among people with type 2 diabetes at diagnosis remains unclear. Materials and Methods We assessed the per allele impact of the rs7903146 T‐allele on clinical characteristics and complication risk in 9231 individuals with type 2 diabetes at diagnosis and over a 10‐year follow‐up period. Log‐binomial and robust Poisson regression analyses were used to estimate prevalence ratios for clinical characteristics and macro‐ and microvascular complications at diabetes onset, while Cox regression was applied to estimate the risk of complications post‐diagnosis. Analyses were adjusted for sex, calendar year at birth, age at enrollment and diabetes duration.

Results

The per T‐allele impact was associated with 0.6 kg/m 2 (95% CI: 0.4, 0.8) lower BMI, 1.4 cm (95% CI: 1.0, 1.8) smaller waist circumference, 5.6% (95% CI: 4.2, 7.0) lower insulin secretion and 5.0% (95% CI: 3.3, 6.7) higher insulin sensitivity. Over 10 years, the per T‐allele impact was associated with lower risks for major adverse cardiovascular events (0.87 [95% CI 0.79, 0.95]), myocardial infarction (0.82 [95% CI: 0.72, 0.93]) and heart failure (0.85 [95% CI 0.73, 1.00]), with no significant impact on microvascular complications.

Conclusions

The TCF7L2 variant is associated with less obesity, lower insulin secretion and higher insulin action at diabetes onset, and decreased risk of cardiovascular events following type 2 diabetes onset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Transcription Factor 7-Like 2 ProteinDiabetic AngiopathiesDiabetes ComplicationsHumansFemaleMaleMiddle AgedAgedPolymorphism, Single NucleotideGenetic Predisposition to DiseaseRisk FactorsAdultAlleles

Stichwörter der Autor:innen

cardiovascular diseasecohort studydiabetes complicationsgenetic predispositionobservational studytype 2 diabetes

Substanzen

Transcription Factor 7-Like 2 ProteinTCF7L2 protein, human

Autor:innen und Institutionen

  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Department of Clinical Epidemiology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
  • Lund University Diabetes Center, Lund University, Lund, Sweden.
  • Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
  • Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Aleksander L Hansen, Mette K Andersen, Leonie M Engelhard, Charlotte Brøns, Torben Hansen, Jens S Nielsen, Peter Vestergaard, Kurt Højlund, Niels Jessen, Michael H Olsen, Reimar W Thomsen, Allan Vaag

Förderung

  • Region Syddanmark
  • Sundhedsstyrelsen
  • Danish Agency for Science and Higher Education
  • Novo Nordisk Fonden
  • Diabetesforeningen
  • Swedish Research Council
  • Vetenskapsrådet

Zitieren

APA

Hansen, A. L., Andersen, M. K., Engelhard, L. M., Brøns, C., Hansen, T., Nielsen, J. S., Vestergaard, P., Højlund, K., Jessen, N., Olsen, M. H., Thomsen, R. W., & Vaag, A. (2025). Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 27(4), 2002-2011. https://doi.org/10.1111/dom.16193

Vancouver

Hansen AL, Andersen MK, Engelhard LM, Brøns C, Hansen T, Nielsen JS, et al. Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2025;27(4):2002-2011. doi:10.1111/dom.16193

BibTeX
@article{Hansen2025,
  author = {Hansen, Aleksander L and Andersen, Mette K and Engelhard, Leonie M and Brøns, Charlotte and Hansen, Torben and Nielsen, Jens S and Vestergaard, Peter and Højlund, Kurt and Jessen, Niels and Olsen, Michael H and Thomsen, Reimar W and Vaag, Allan},
  title = {Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {4},
  pages = {2002--2011},
  doi = {10.1111/dom.16193}
}
Kostenlos starten →